SCHEMBL1749222

SCHEMBL1749222

CC(=O)CNC1CCN(c2ccc(NC(=O)c3ccc(OC4CCCC4)cc3)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.52
MAPT P10636 8/20 0.48
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 5/20 0.48
HSD17B10 Q99714 3/20 0.48
ALOX15 P16050 2/20 0.48
RAB9A P51151 3/20 0.48
MCL1 Q07820 2/20 0.48
NR4A1 P22736 1/20 0.48
USP2 O75604 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
ACACB O00763 4/20 0.46
MEN1 O00255 2/20 0.45
NPC1 O15118 2/20 0.44
HIF1A Q16665 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1750761 0.89 MCHR1 (0.47) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749538 0.86 MCHR1 (0.60) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749380 0.85 HDAC1 (0.54) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1750162 0.85 MCHR1 (0.52) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749244 0.85 MAPT (0.63) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749171 0.85 MAPT (0.63) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1750063 0.85 MCHR1 (0.53) MCHR1MAPTALDH1A1KMT2ARAB9A
SCHEMBL1748977 0.84 MCHR1 (0.51) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749192 0.83 MAPT (0.52) MCHR1MAPTALDH1A1KMT2AHSD17B10
SCHEMBL1749126 0.83 MAPT (0.65) MCHR1MAPTALDH1A1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968550-B2 Substituted N-aryl heterocycles, process for their preparation and their use as medicaments AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2011-06-28 US disclosed
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-09-06 US disclosed
US-7223788-B2 therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207991-A1 Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments CYP11B2, CYP11B1, NQO1 MCHR1 2068/4885MAPT 4800/4885ALDH1A1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.